.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Baxter
US Army
US Department of Justice
Fish and Richardson
Dow
Colorcon
Daiichi Sankyo
Medtronic
Deloitte

Generated: July 22, 2017

DrugPatentWatch Database Preview

EMEND Drug Profile

« Back to Dashboard

What is the patent landscape for Emend, and when can generic versions of Emend launch?

Emend is a drug marketed by Merck And Co Inc, Merck, and Msd Merck Co. and is included in three NDAs. There are three patents protecting this drug and four Paragraph IV challenges.

This drug has one hundred and twenty-one patent family members in forty-eight countries.

The generic ingredient in EMEND is aprepitant. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aprepitant profile page.

Summary for Tradename: EMEND

Patents:3
Applicants:3
NDAs:3
Suppliers / Packagers: see list3
Bulk Api Vendors: see list64
Clinical Trials: see list27
Patent Applications: see list58
Drug Prices:see details
DailyMed Link:EMEND at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Merck Co
EMEND
aprepitant
FOR SUSPENSION;ORAL207865-001Dec 17, 2015RXYesYes► Subscribe► Subscribe
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-002Mar 26, 2003ABRXYesYes► Subscribe► Subscribe
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-001Jan 25, 2008DISCNYesNo5,691,336► SubscribeYY ► Subscribe
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-002Mar 26, 2003ABRXYesYes6,096,742► Subscribe ► Subscribe
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-003Jun 30, 2006ABRXYesNo8,258,132► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EMEND

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-001Mar 26, 20035,145,684► Subscribe
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-002Nov 12, 20105,512,570► Subscribe
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-002Nov 12, 20105,538,982► Subscribe
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-003Jun 30, 20066,235,735► Subscribe
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-001Mar 26, 20035,538,982► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EMEND

Drugname Dosage Strength RLD Submissiondate
aprepitantfor Oral Suspension125 mg/KitEmend11/23/2016
fosaprepitant dimeglumineInjection115 mg/vialEmend1/25/2012
fosaprepitant dimeglumineInjection150 mg/vialEmend1/25/2012
aprepitantCapsule40 mg, 80 mg and 125 mgEmend11/3/2008

Non-Orange Book Patents for Tradename: EMEND

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,432,953 Polymorphic form of a tachykinin receptor antagonist► Subscribe
6,583,142 Polymorphic form of a tachykinin receptor antagonist► Subscribe
5,512,570 Treatment of emesis with morpholine tachykinin receptor antagonists► Subscribe
5,780,467 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists► Subscribe
6,229,010 Polymorphic form of a tachykinin receptor antagonist► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EMEND

Country Document Number Estimated Expiration
Finland963450► Subscribe
Serbia49980► Subscribe
Canada2293836► Subscribe
Turkey9903299► Subscribe
Algeria2551► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EMEND

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2004002,C0734381Lithuania► SubscribePRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
C/GB04/011United Kingdom► SubscribePRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
2004Austria► SubscribePRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
C/GB08/021United Kingdom► SubscribePRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
2004002Lithuania► SubscribePRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Queensland Health
Cipla
Novartis
Harvard Business School
QuintilesIMS
McKesson
Cerilliant
Farmers Insurance
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot